Claims
- 1. A topical composition consisting essentially of:
- i) laureth-4, present in about 1 percent by weight of the total composition;
- ii) propylene glycol, present in about 2 percent by weight of the total composition;
- iii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- iv) trans-retinoic acid, present in about 0.01 percent by weight of the total composition; and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
- 2. A method for transepithelial delivery of trans-retinoic acid to a human, comprising applying to the skin of the human a topical composition consisting essentially of
- i) laureth-4, present in about 1 percent by weight of the total composition;
- ii) propylene glycol, present in about 2 percent by weight of the total composition;
- iii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- iv) trans-retinoic acid, present in about 0.01 percent by weight of the total composition; and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
- 3. A topical composition consisting essentially of:
- i) laureth-4, present in about 1 percent by weight of the total composition;
- ii) propylene glycol, present in about 2 percent by weight of the total composition;
- iii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- iv) an effective amount of a pharmaceutically acceptable drug, wherein the drug is effective when administered topically; and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
- 4. A method for transepithelial delivery of a drug to a human, comprising applying to the skin of the human a topical composition consisting essentially of:
- i) laureth-4, present in about 1 percent by weight of the total composition;
- ii) propylene glycol, present in about 2 percent by weight of the total composition;
- iii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- iv) an effective amount of a pharmaceutically acceptable drug, wherein the drug is effective when administered topically; and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
- 5. A topical composition consisting essentially of:
- i) SDA-40 200 proof, present in about 36.8 percent by weight of the total composition;
- i) butylated hydroxyanisole, present in about 0.15 percent by weight of the total composition;
- ii) glycerin, present in about 2 percent by weight of the total composition;
- iv) propylene glycol, present in about 2 percent by weight of the total composition;
- v) purified distilled water, present in about 40 percent by weight of the total composition;
- vi) pantethine, present in about 0.03 percent by weight of the total composition;
- vii) laureth-4, present in about 1 percent by weight of the total composition;
- viii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- ix) disodium EDTA, present in about 0.15 percent by weight of the total composition; and
- v) distilled water.
- 6. The composition of claim 5 further comprising a pharmaceutically active drug, wherein the drug is effective when administered topically.
- 7. The composition of claim 6 wherein that drug is trans-retinoic acid.
- 8. A method for transepithelial delivery of a drug to a human, comprising applying to the skin of the human a topical composition consisting essentially of:
- i) SDA-40 200 proof present in about 36.8 percent by weight of the total composition;
- ii) butylated hydroxyanisole, present in about 0.15 percent by weight of the total composition;
- iii) glycerin USP 96 percent, present in about 2 percent by weight of the total composition;
- iv) propylene glycol, present in about 2 percent by weight of the total composition;
- v) purified distilled water, present in about 40 percent by weight of the total composition;
- vi) pantethine 80 percent, present in about 0.03 percent by weight of the total composition;
- vii) laureth-4, present in about I percent by weight of the total composition;
- viii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- ix) disodium EDTA, present in about 0.15 percent by weight of the total composition;
- x) a pharmaceutically active drug, wherein the drug is effective when administered topically; and
- xi) distilled water.
- 9. The composition of claim 8 wherein that drug is trans-retinoic acid.
Parent Case Info
This is a continuation of application Ser. No. 08/199,989, filed Feb. 22, 1994, which is a continuation of application Ser. No. 07/944,020, filed Sep. 11, 1992, which is a continuation of application Ser. No. 07/677,375, filed Mar. 27, 1991, which is a continuation of application Ser. No. 07/334,511, filed Apr. 6, 1989, all abandoned.
US Referenced Citations (14)
Non-Patent Literature Citations (6)
Entry |
Weiss, J.S., et al., "Topical Tretinoin Improves Photoaged Skin: A Double-Blind Vehicle-Controlled Study," Journal of the American Medical Association, vol. 259, Jan. 22/29, 1988, pp. 527-532. |
Weiss, R., "Wrestling with Wrinkles," Science News, vol. 134, Sep. 24, 1988, pp. 200-202. |
Merdi Index, 10.sup.th Ed 1985, Abstract 7756. |
A.B. Barua and J.A. Olson, Percutaneous Absoption, Excretion and Metabolism of All-trans-Retinoyl B-Glucuronide and of All trans-Retinoic Acid in the Rat, 1996 Skin Pharmacol; 9: 17-26 |
Commonwealth of Virginia Pharmacy Act, p. 34, Jul. 1, 1993. |
McCutcheon's Detergents & Emulsifiers, 1971 Amnd., p. 24. |
Continuations (4)
|
Number |
Date |
Country |
Parent |
199989 |
Feb 1994 |
|
Parent |
944020 |
Sep 1992 |
|
Parent |
677375 |
Mar 1991 |
|
Parent |
334511 |
Apr 1989 |
|